AB Corporate Bond ETF (NASDAQ:EYEG) Stock Crosses Below Two Hundred Day Moving Average – Time to Sell?

AB Corporate Bond ETF (NASDAQ:EYEG) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $35.78 and traded as low as $35.37. AB Corporate Bond ETF shares last traded at $35.37, with a volume of 15 shares.

AB Corporate Bond ETF Stock Performance

The company has a current ratio of 3.07, a quick ratio of 3.07 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $28.30 million, a PE ratio of -21.05 and a beta of 0.18. The firm’s 50-day simple moving average is $35.42 and its two-hundred day simple moving average is $35.78.

AB Corporate Bond ETF Announces Dividend

The company also recently disclosed a monthly dividend, which was paid on Wednesday, May 6th. Shareholders of record on Friday, May 1st were given a dividend of $0.1404 per share. This represents a c) annualized dividend and a yield of 4.8%. The ex-dividend date was Friday, May 1st. AB Corporate Bond ETF’s payout ratio is presently -103.57%.

Hedge Funds Weigh In On AB Corporate Bond ETF

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Kestra Advisory Services LLC purchased a new position in AB Corporate Bond ETF during the 4th quarter worth approximately $34,000. Jane Street Group LLC purchased a new position in AB Corporate Bond ETF during the 2nd quarter worth approximately $232,000. Finally, Wealth Enhancement Advisory Services LLC grew its position in AB Corporate Bond ETF by 6.2% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 119,017 shares of the specialty pharmaceutical company’s stock worth $4,301,000 after purchasing an additional 6,988 shares in the last quarter. 64.16% of the stock is currently owned by hedge funds and other institutional investors.

AB Corporate Bond ETF Company Profile

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.